https://www.selleckchem.com/products/n6f11.html
The median PFS interval was 2.3months for the patients with stage IV GC. Nine patients (29%) had a low baseline PMI, and these patients had significantly shorter median PFS than the group with a non-low baseline PMI (0.5months vs. 2.4months, P = 0.004). As a surrogate marker for skeletal muscle loss, the PMI may be useful for predicting the response to nivolumab among patients with advanced GC. As a surrogate marker for skeletal muscle loss, the PMI may be useful for predicting the response to nivolumab among patients with advanced GC. Ar
Curtir
Comentario
Compartilhar
